- ADC Therapeutics press release ( NYSE: ADCT ): Q2 Non-GAAP EPS of -$0.73.
- Revenue of $17.29M (+359.8% Y/Y) misses by $13.93M .
- “The ZYNLONTA® launch is advancing steadily as we continue to increase awareness and advocacy. There is significant opportunity ahead and we have a focused plan in place to achieve continued growth in the coming quarters,” commented Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “Our pipeline of hematology and solid tumor programs is progressing well with impressive Cami Phase 2 data in Hodgkin lymphoma presented at the EHA Congress in June. Our recent license agreement with Sobi® in Europe gives us worldwide access for ZYNLONTA. We have a strong cash runway extending into early 2025 which makes us well-positioned to execute on our key objectives.”
For further details see:
ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M